Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: Correlation with renal injury

Journal of Cellular and Molecular Medicine

Volumn 10, Issue 4, 2006, Pages 838-851

  Kassimatis, Theodoros I ^a,b   Giannopoulou, Ioanna ^c   Koumoundourou, Dimitra ^a   Theodorakopoulou, Emily ^d   Varakis, Ioannis ^a   Nakopoulou, Lydia ^c  

^a UNIVERSITY OF PATRAS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Glomerulonephritis; P300; PSmad2 3; Renal fibrosis

Indexed keywords

EID: 84867216946     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.2755/jcmm010.004.05     Document Type: Article

References (50)

1. Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990; 19: 245-7.
2. Robert AB, Sporn MB. The transforming growth factor-βs. In: Peptide Growth Factors and Their Receptors, edited by Sporn MB, Robert AB, Berlin, Springer-Verlag, 1991, pp 419-472.
3. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000; 15: 290-301.
4. Border WA, Noble NA. TGF-beta in kidney fibrosis: A target for gene therapy. Kidney Int. 1997; 51: 1388-96.
5. Böttinger EP, Bitzer M. TGF-β signaling in renal disease. J Am Soc Nephrol. 2002; 13: 2600-10.
6. Yamamoto T, NOble NA, Cohen AH, Nasst CC, Hishida A, Gold LI, Border WA. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. 1996; 49: 461-9.
7. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor-β in human disease. N Engl J Med. 2000; 342: 1350-8.
8. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature 1994; 370: 341-7.
9. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, ten Dijke P. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 1997; 16: 5353-62.
10. Miyazono K, ten Dijke P, Heldin C-H. TGF-β signaling by Smad proteins. Adv Immunol. 2000; 75: 115-57.
11. Macias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL. MADR2 is a substrate of the TGF-β receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996; 87: 1215-24.
12. Zhang Y, Feng X-H, Wu RY, Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature 1996; 383: 168-72.
13. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF-β-inducible elements in the promoter of human plasminogen activator inhibitor-type I gene. EMBO J 1998; 17: 3091-3100.
14. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern SE. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell. 1998; 1: 611-17.
15. Massague J, Wotton D. Transcriptional control by TGF-β/Smad signaling. EMBO J. 2000; 19: 1745-54.
16. Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
17. de Caestecker MP, Yahata T, Wang D, Parks WT, Huang S, Hill CS, Shioda T, Roberts AB, Lechleider RJ. The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. J Biol Chem. 2000; 275: 2115-22.
18. Shen X, Hu PP, Liberati NT, Datto MB, Frederick JP, Wang XF. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with co-activator p300/CREB-binding protein. Mol Biol Cell. 1998; 9: 3309-19.
19. Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 1999; 286: 771-4.
20. Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 2001; 158: 1653-63.
21. Kim JH, Kim BK, Moon KC, Hong HK, Lee HS. Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 2003; 64:1715-21.
22. Kanamaru Y, Nakao A, Tanaka Y, Inagaki Y, Ushio H, Shirato I, Horikoshi S, Okumura K, Ogawa H, Tomino Y. Involvement of p300 in TGF-beta/Smad-pathway-mediated alpha2(I) collagen expression in mouse mesangial cells. Nephron Exp Nephrol. 2003; 95: e36-42.
23. Wang W, Koka V, Lan H. Transforming growth factor-β and Smad signaling in kidney diseases. Nephrology 2005; 10: 48-56.
24. Bussolati G, Gugliotta P, Volante M, Pace M, Papotti M. Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology 1997; 31: 400-7.
25. Williams MA, Lowrie JI. Fixation of tissue for morphometric study; in Bach FH, Lock EA, (eds): Nephrotoxicity in experimental and clinical situations. Dordrecht, Martinus Nijhoff, 1987, part I, pp 141-66.
26. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol. 2002; 13: 1464-72.
27. Yamashita S. Ontogenic expression of estrogen receptor co-activators in the reproductive tract of female mice neonatally exposed to diethylstilbestrol. Reprod Toxicol 2004; 18: 275-84.
28. + with two three step avidinbiotin techniques. Appl Immunohistochem 1998; 61: 3-10.
29. TM+ system: a new immunohistochemical method for diagnostics and research. Critical comparison with APAAP, ChemMateTM, CSA, LABC, and SABC techniques. J Clin Pathol. 1998; 51: 506-11.
30. Flanders K, Kim E, Roberts A. Immunohistochemical expression of Smads 1-6 in the 15-day gestation mouse embryo: signaling by BMPs and TGF-betas. Dev Dyn. 2001; 220: 141-54.
31. Vrljicak P, Myburgh D, Ryan AK. Smad expression during kidney development. Am J Physiol Renal Physiol. 2004; 286: F625-33.
32. Ando T, Okuda S, Yanagida T, Fujishima M. Localization of TGF-beta and its receptors in the kidney. Miner Electrolyte Metab. 1998; 24: 149-53.
33. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest. 1993; 92: 1366-72.
34. Law F, Rizzoli R, Bonjour JP. Transforming growth factor-beta inhibits phosphate transport in renal epithelial cells. Am J Physiol. 1993; 264: F623-8.
35. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation and development. Genes Dev. 2000; 14:1553-77.
36. Ten Dijke P, Goumans MJ, Itoh F, Itoh S. Regulation of cell proliferation by Smad proteins. J Cell Physiol. 2002; 191: 1-16.
37. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001; 29: 117-29.
38. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst. 2000; 92: 1388-402.
39. Giordano A, Avantaggiati ML. p300 and CBP, partners for life and death. J Cell Physiol. 1999; 181: 218-30.
40. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004; 23: 4225-31.
41. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen de AL, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res. 2003; 63: 7638-40.
42. Patel P, Varghese E, Ding G, Fan S, Kapasi A, Reddy K, Franki N, Nahar N, Singhal P. Transforming growth factor beta induces mesangial cell apoptosis through NO- and p53-dependent and -independent pathways. J Investig Med. 2000; 48: 403-10.
43. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 2002; 13: 413-21.
44. McCartney-Francis N, Jin W, Wahl SM. Aberrant Toll receptor expression and endotoxin hypersensitivity in mice lacking a functional TGF-beta 1 signaling pathway. J Immunol. 2004; 172: 3814-21.
45. McKarns SC, Schwartz RH, Kaminski NE. Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol. 2004; 172: 4275-84.
46. Feinberg MW, Shimizu K, Lebedeva M, Haspel R, Takayama K, Chen Z, Frederick JP, Wang XF, Simon DI, Libby P, Mitchell RN, Jain MK. Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation. Circ Res. 2004; 94: 601-8.
47. Vanden Berghe W, Vermeulen L, Delerive P, De Bosscher K, Staels B, Haegeman G. A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv Exp Med Biol. 2004; 544: 181-96.
48. Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F, Egido J. Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension 2001; 37: 1171-8.
49. Rangan GK, Wang Y, Tay YC, Harris DC. Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int. 1999; 56: 118-34.
50. Bhattacharyya S, Ghosh AK, Pannu J, Mori Y, Takagawa S, Chen G, Trojanowska M, Gilliam AC, Varga J. Fibroblast expression of the co-activator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum. 2005; 52: 1248-58.